Daniel Burch, a former executive with GlaxoSmithKline, has joined startup CeNeRx BioPharma as its executive vice president for research and development as well as chief medical officer.
The lead product for CeNeRx targets depression and anxiety. The company closed on $15 million in venture financing in late 2005.
Burch has 15 years of experience in new medicine development, having worked at GSK, Abbott Laboratories and SmithKline Beecham. At GSK he was senior vice president and head of the neurosciences medicine development center.
A graduate of the Vanderbilt University School of Medicine, he earned an MBA at the Wharton School at the University of Pennsylvania.